From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
| Autor: | Jacob E. Michalski, David A. Schwartz, Jonathan S. Kurche |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
ARDS Pulmonary Fibrosis Disease medicine.disease_cause Article Physiology (medical) Pandemic Pulmonary fibrosis medicine Humans Intensive care medicine Pandemics Coronavirus Respiratory Distress Syndrome business.industry SARS-CoV-2 Biochemistry (medical) Public Health Environmental and Occupational Health COVID-19 Sequela General Medicine medicine.disease Pathophysiology Pneumonia business |
| Zdroj: | Translational Research |
| ISSN: | 1878-1810 1931-5244 |
| Popis: | While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and scientific communites since it was first reported in late 2019, we are only beginning to understand the chronic health burdens associated with this disease. Although COVID-19 is a multi-systemic disease, the lungs are the primary source of infection and injury, resulting in pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). Given that pulmonary fibrosis is a well-recognized sequela of ARDS, many have questioned whether COVID-19 survivors will face long-term pulmonary consequences. This review is aimed at integrating our understanding of the pathophysiologic mechanisms underlying fibroproliferative ARDS with our current knowledge of the pulmonary consequences of COVID-19 disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect